Clinical Trial: Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa Concentrate in Patients With Acquired Haemophilia and in Patients With Haemophilia
Brief Summary:
Occurrence of inhibitors to coagulation factor VIII is diagnosed in ~30% patients with haemophilia A. Presence of inhibitor with a titre >5 BU/ml requires the use of by-passing agents: recombinant activated Factor VIIa concentrate (rFVIIa) and/or activated prothrombin complex concentrate (APCC). Similarly, haemorrhagic complications in patients with acquired haemophilia and inhibitor titre >5 BU/ml should be treated with by-passing agents.
Response to treatment with by-passing agents is patient-specific, and can vary in the same patient during subsequent bleedings. Some patients have good response to both products, however in other patients a better bleeding control is provided by one of the mentioned above agents (APCC or rFVIIa). There are clinical situations when severe bleedings requires an alternate use of both these agents.
Traditional methods of laboratory tests used post-treatment in patients with haemophilia without inhibitors are useless in the presence of inhibitor. Laboratory monitoring of therapy with by-passing agents is possible with the use of global tests for the coagulation process assessment, which are as follows: thrombin generation assay (TGA) and thromboelastometry (TEM).
Several studies revealed that TGA allows a monitoring of therapy with by-passing agents in patients with haemophilia A and inhibitor - the choice of the most effective treatment option - agent type and its dose, as well as laboratory assessment of treatment efficacy.
Up to date, laboratory tests assessing the efficacy of by-passing agents in patients with acquired haemophilia were not conducted.
In Factor VIII or IX deficiency conditions, fibrin's fibres generated by thrombin are
Detailed Summary: This section is Not applicable
Sponsor: Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus
Current Primary Outcome: Assessment of patient's individual response to therapy with by-passing agents by simultaneous use of TGA and TEM methods. [ Time Frame: 48 hours ]
Original Primary Outcome: Assessment of patient's individual response to therapy with by-passing agents by simultaneous use of TGA and TEM methods. [ Time Frame: 48 hours ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus
Dates:
Date Received: May 14, 2013
Date Started: April 2014
Date Completion: June 2016
Last Updated: December 17, 2015
Last Verified: December 2015